PEG conjugated VEGF siRNA for anti-angiogenic gene therapy

Journal of Controlled Release

Volumn 116, Issue 2 SPEC. ISS., 2006, Pages 123-129

  Kim, Sun Hwa ^a   Jeong, Ji Hoon ^b   Lee, Soo Hyun ^a   Kim, Sung Wan ^b   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Gene delivery; Polyelectrolyte complex micelles; siRNA PEG conjugate; Vascular endothelial growth factor

Indexed keywords

DEGRADATION; ENZYMES; GENETIC ENGINEERING; GROWTH KINETICS; MICELLES; POLYELECTROLYTES; POLYETHYLENE GLYCOLS;

GENE DELIVERY; POLYELECTROLYTE COMPLEX MICELLES; SIRNA-PEG CONJUGATE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

RNA;

ANGIOGENESIS INHIBITOR; DISULFIDE; MACROGOL; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DISULFIDE BOND; DNA CLEAVAGE; DRUG CONJUGATION; DRUG STABILITY; DRUG SYNTHESIS; ENZYME DEGRADATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MICELLE; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33845216721     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.05.023     Document Type: Article

References (37)

1. Bots M., Vergeldt F., Wolters-Arts M., Weterings K., Van As H., and Mariani C. Aquaporins of the PIP2 class are required for efficient anther dehiscence in tobacco. Plant Physiol. 137 (2005) 1049-1056
2. Gartel A.L., and Kandel E.S. RNA interference in cancer. Biomol. Eng. 23 (2006) 17-34
3. Robson M.G., and Sacks S.H. RNA interference - a new experimental and therapeutic tool. In. Curr. Opin. Nephrol. Hypertens. 14 (2005) 558-560
4. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
5. Zamore P.D., Tuschl T., Sharp P.A., and Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 (2000) 25-33
6. Jones L., Hamilton A.J., Voinnet O., Thomas C.L., Maule A.J., and Baulcombe D.C. RNA-DNA interactions and DNA methylation in post-transcriptional gene silencing. Plant Cell 11 (1999) 2291-2301
7. Smart N., Scambler P.J., and Riley P.R. A rapid and sensitive assay for quantification of siRNA efficiency and specificity. Biol. Proced. Online 7 (2005) 1-7
8. Tebes S.J., and Kruk P.A. The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer. Gynecol. Oncol. 99 (2005) 736-741
9. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., and Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 22 (2004) 326-330
10. Sagara K., and Kim S.W. A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes. J. Control. Release 79 (2002) 271-281
11. Meidan V.M., Glezer J., Amariglio N., Cohen J.S., and Barenholz Y. Oligonucleotide lipoplexes: the influence of oligonucleotide composition on complexation. Biochim. Biophys. Acta 1568 (2001) 177-182
12. Maeda Y., Fukushima K., Nishizaki K., and Smith R.J. In vitro and in vivo suppression of GJB2 expression by RNA interference. Hum. Mol. Genet. 14 (2005) 1641-1650
13. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., and Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12 (2005) 461-466
14. Jeong J.H., Kim S.W., and Park T.G. A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J. Control. Release 93 (2003) 183-191
15. Jeong J.H., Kim S.H., Kim S.W., and Park T.G. Polyelectrolyte complexmicelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemicadministration on tumor growth. Bioconjug. Chem. 16 (2005) 1034-1037
16. Jeong J.H., Kim S.H., Kim S.W., and Park T.G. In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles. J. Biomater. Sci., Polym. Ed. 16 (2005) 1409-1419
17. Wang W., and Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol. Rev. 50 (1998) 335-356
18. Jo Y.W., Youn Y.S., Lee S.H., Kim B.M., Kang S.H., Yoo M., Choi E.C., and Lee K.C. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int. J. Pharm. 309 (2006) 87-93
19. Diwan M., and Park T.G. Stabilization of recombinant interferon-alpha by PEGylation for encapsulation in PLGA microspheres. Int. J. Pharm. 252 (2003) 111-122
20. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., and Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
21. Tomar R.S., Matta H., and Chaudhary P.M. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 22 (2003) 5712-5715
22. Oishi M., Nagatsugi F., Sasaki S., Nagasaki Y., and Kataoka K. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. ChemBioChem 6 (2005) 718-725
23. Oishi M., Nagasaki Y., Itaka K., Nishiyama N., and Kataoka K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. JACS 127 (2005) 1624-1625
24. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., and Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11393-11398
25. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
26. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146 (1995) 1029-1039
27. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
28. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., and Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
29. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
30. Tao J., Tu Y.T., Huang C.Z., Feng A.P., Wu Q., Lian Y.J., Zhang L.X., Zhang X.P., and Shen G.X. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br. J. Dermatol. 153 (2005) 715-724
31. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., and Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64 (2004) 3365-3370
32. Braasch D.A., Jensen S., Liu Y., Kaur K., Arar K., White M.A., and Corey D.R. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42 (2003) 7967-1975
33. Prakash T.P., Allerson C.R., Dande P., Vickers T.A., Sioufi N., Jarres R., Baker B.R., Swayze E.E., Griffey R.H., and Bhat B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48 (2005) 4247-4253
34. Amarzguioui M., Holen T., Babaie E., and Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31 (2003) 589-595
35. Kalota A., Shetzline S.E., and Gewirtz A.M. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol. Ther. 3 (2004) 4-12
36. Sung S.J., Min S.H., Cho K.Y., Lee S., Min Y.J., Yeom Y.I., and Park J.K. Effect of polyethylene glycol on gene delivery of polyethylenimine. Biol. Pharm. Bull. 26 (2003) 492-500
37. Merdan T., Kunath K., Petersen H., Bakowsky Y., Voigt K.H., Kopecek J., and Kissel T. PEGylation of poly(ethyleneimine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependentmannerafter intravenous injection into mice. Bioconjug. Chem. 16 (2005) 785-792